Enveric Biosciences shares are trading lower. The company announced a manuscript detailing the development of novel psilocin prodrugs for the treatment of anxiety and other mental health disorders.
Portfolio Pulse from Benzinga Newsdesk
Enveric Biosciences shares are trading lower after the company announced a manuscript detailing the development of novel psilocin prodrugs for the treatment of anxiety and other mental health disorders.
May 22, 2023 | 5:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Enveric Biosciences shares are trading lower following the announcement of a manuscript on the development of novel psilocin prodrugs for anxiety and mental health disorders.
Enveric Biosciences shares are trading lower due to the announcement of a manuscript detailing the development of novel psilocin prodrugs. This news may have caused uncertainty among investors about the company's progress and potential market competition, leading to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100